

15 October 2019

ASX ANNOUNCEMENT

CLARIFICATION: ADMEDUS INKS \$A36.2M DEAL FOR CARDIOCEL® AND VASCUCEL® PATCH BUSINESS

Admedus Limited (AHZ or the Company) provides the following clarification in relation to the \$22.8M upfront payment for the sale of its CardioCel® and VascuCel® patch business to U.S based LeMaitre Vascular Inc. (NASDAQ: LMAT, 'LeMaitre'). The A\$22.8M consideration is exclusive of the two instalments of \$A1m but does reflect the proceeds to be paid by LeMaitre on delivery of stock ordered on completion of the transaction. The cash received by the Company on the completion date was A\$21.2M.

ENDS

About Admedus Limited (ASX: AHZ)

Admedus Ltd is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Its focus is on developing next generation technologies with world class partners.

For more information:

Admedus@we-buchan.com

www.admedus.com

Twitter: @Admedus

Facebook: www.facebook.com/pages/Admedus

Admedus Limited

Registered Office:

Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland 4066

Customer Service:

T: 1300 550 310 F: 1300 880 398 International: T: +61 (0)7 3152 3200 F: +61 (0)7 3152 3299

E: info@admedus.com W: admedus.com

